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• After almost 75 years of research and four Nobel prizes 
awarded for insulin-related investigations, we still do not un- 
derstand how insulin works. Of course, substantial progress 
has been made and there are some clues. We review in vivo 
insulin action from the moment of insulin biosynthesis in the 
pancreatic fi-cell to insulin action on effector systems in tar- 
get tissues. The mechanism of insulin action at the whole body, 
tissue and cellular level is discussed. In addition, factors and 
conditions influencing insulin action and events leading to 
insulin resistance are summarized. Finally, the reader is in- 
troduced into the principles of the hyperinsulinaemic, 
euglycaemic clamp technique which is considered the "golden 
standard" for measurement of insulin action and resistance 
in vivo. An example is given how to clamp conscious rats in a 
proper way.  
INTRODUCTION 
• Insulin is a 6 kD, double chain 51 aminoacid polypep- 
tide which is produced in the pancreatic R-cell, the first pro- 
tein formed being preproinsulin (Fig. 1). It is converted by pro- 
teolytic steps to proinsulin by removing the signal peptide. 
Proinsulin is finally cleaved into insulin and a C-chain, also 
called connective peptide (C-peptide) (1-3). Insulin is secreted 
into the portal circulation, in parallel with an equimolar amount 
of C-peptide and a small amount (±5%) of unconverted proin- 
sulin. Metabolic, hormonal, and neural factors modulate the 
insulin secretion (4-7). This modulation is neccessary to en- 
sure that the adequate amount of insulin is present in the blood 
to meet with the changing metabolic demands. The main meta- 
bolic task of insulin is to regulate the glucose uptake in the 
insulin-sensitive skeletal muscle, liver and fat tissues. During 
a meal, a period of fasting, rest or physical exercise, glucose 
homeostasis has to be maintained to meet the energy require- 
ments of different tissues at any time. Together with counter- 
regulatory hormones, insulin guards glucose homeostasis, pre- 
venting both hypoglycemia and hyperglycemia. In general, 
plasma glucose levels are kept between 4 and 7 mmol/1. 
 
INSULIN ITINERARY IN THE BODY AND ITS 
GENERAL ACTION OH METABOLISM 
• The body contains roughly three insulin-sensitive tis- 
sues in which insulin exerts its metabolic effects (8,9). Insulin 
interacts with liver, muscle and fat cells by binding to insulin 
receptors which are present in the cell membrane. Upon bind- 
ing to the receptor, insulin causes pleiotropic effects in target 
cells, probably brought about by multiple independent mecha- 
nisms (10). These effects can be observed within milliseconds 
(ion fluxes), within seconds to minutes (carbohydrate and lipid 
metabolism), or in tens of minutes to hours (gene expression) 
(11). In general, most of these actions are of an anabolic char- 
acter. In the liver, insulin suppresses glucose production and 
output by promoting glycogen synthesis and reducing gluco- 
neogenesis. In addition, it stimulates hepatic lipogenesis. In- 
sulin does not exert a direct stimulatory effect on hepatic glu- 
cose transport. In muscle cells and adipocytes, insulin stimu- 
lates glucose transport, glycogen synthesis, glucose oxidation 
and lipogenesis (8,9). Glucose production and output is not 
present in muscle and fat because these tissues lack glucose-6- 




Figure 1. Preproinsulin consisting of a signal peptide, a C-chain (C-peptide) and insulin. Insulin consists of an A- and B- 
chain held together by two disulflde bonds. The proteolytic processing sites are indicated by lines between some amino acid 
residues. Amino acids are designated by their one-letter abbreviations. Adapted from Ebberink et al (3). 
  
The first target tissue which insulin encounters after its secre- 
tion is the liver. The liver removes approximately 50% of the 
amount of insulin which is present in the vascular portal sys- 
tem (13-16). First passage hepatic extraction of insulin from 
the plasma is a variable process and the liver can change the 
plasma clearance rate of insulin under certain conditions (17). 
It has been described that hepatic insulin removal strongly 
depends on the prevailing plasma glucose levels (18,19). 
Hyperglycemia would reduce hepatic insulin degradation 
which then leads to higher peripheral plasma insulin levels. 
This in turn results in a stronger insulin signal in muscle and 
fat tissues which leads to an increase in cellular glucose up- 
take and a subsequent reduction in plasma glucose levels. This 
implies that the liver determines for a substantial part to which 
plasma insulin levels the peripheral tissues are exposed to. 
Under normal conditions, the half-life of insulin in the blood 
is less than 5 minutes (2,20). Insulin binds to the plasma mem- 
brane receptor. Some insulin is then partially degraded on the 
membrane by insulin degrading enzymes and some insulin 
can be released intact. Receptor-bound insulin migrates by en- 
docytosis towards various intracellular sites, including 
endosomes and lysosomes, and intact insulin and partially de- 
graded insulin reach the nucleus (13). The major part of insu- 
lin degradation occurs in the liver and, a lesser one, in the 
kidneys. Receptor-mediated insulin internalization in muscle 
and fat cells plays a role in the removal process of insulin 
from the blood (13,21). Internalization of the insuline-recep- 
tor complex is one of the processes that terminate the signal 
transduction (22). 
When insulin has passed the liver, it can exert its actions in 
peripheral tissues. A summary of the actions of insulin is given 
in Fig.2 (10). Less known is the effect of insulin in the central 
nervous system (23,24). Insulin is able to increase the net up- 
take of glucose into the brain and it stimulates brain glycogen 
and amino acid synthesis (25,26). Insulin may arise from blood 
via receptor-mediated transcytosis through the brain capillary 
endothelial cells (26) and/or insulin may migrate from the 
blood via the cerebrospinal fluid to the central nervous system 
(27,28). Since insulin binding sites have been found through- 
out the central nervous system (29), it is conceivable that in- 
sulin modulates certain central nervous functions (30). The 
fact that hyperinsulinemia is able to increase sympathetic ner- 
vous system activity (31,32), is in support of this statement. 
•        Mechanism of insulin action 
The cellular action of insulin starts by binding to its mem- 
brane receptor. The receptor is able to recognize the hormone 
with high affinity and a high degree of specificity. Next, the 
receptor produces a transmembrane signal that governs intra- 
cellular metabolism (33-35). The insulin receptor is a 
heterotetrameric glycoprotein consisting of two extracellular 
a-subunits with a molecular mass of 130 kD and two trans- 
membrane ft-subunits with a molecular mass of 95 kD which 
are linked to one another by disulfide bonds (36). The recep- 
tor recycles between the plasma membrane and an intracellu- 
lar pool (37). Approximately 10% of the insulin receptors are 
intracellular in the basal state in rat adipocytes and this in- 
creases to a steady state of about 30% after insulin exposure 
(38). There are some 200 000 insulin receptors in rat adipocyte 
and hepatocyte plasma membrane. Theoretically, each recep- 
tor could bind two insulin molecules but ligation of one bind- 
ing site decreases the affinity of the other site almost 100 fold, 
Insulin is internalized with the receptor and is passed to   
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figure 2. A selection of major effector systems governed by insulin. 
  
endosomes leaving the receptor to be recycled to the plasma 
membrane. 
Transmembrane signaling starts with binding of insulin to 
the oc-subunit which activates a tyrosine kinase in the cyto- 
plasmic domain of the fi-subunit. The B-subunit then autopho- 
sphorylates on tyrosine residues 1146,1150 and 1151 and this 
autophosphorylation activates the receptor tirosine kinase to 
phosphorylate various substrates in the cell which then in turn 
would further transduce the insulin binding signal (34,39). 
Upon maximal insulin binding, approximately one-third of 
the total receptor pool becomes autophosphorylated (40). Re- 
cently, intermolecular phosphorylation of insulin receptors was 
described after insulin binding which could be a mechanism 
for amplification of the insulin binding signal (41). On the 
other hand, inactive insulin receptors (no kinase activity upon 
insulin binding) can inhibit the function of normal receptors, 
which could be a mechanism for weakening the insulin bind- 
ing signal (34). 
Only 10% of the entire insulin receptor pool has to bind insu- 
lin in order to reach a 100% biological effect in the rat. Thus 
90% of the receptors are spare. They function normally and it 
is a random event to which particular receptor insulin is bind- 
ing. This phenomenon is called the spare-receptor concept and 
was first described by Kono & Barham (42). The insulin con- 
centration dependencies for insulin binding to its receptor and 
for the stimulation of glucose transport were compared by 
Simpsonand Cushman (43). The insulin concentration needed 
for a half-maximal response (ED.0) is 0.14 nM for glucose 
transport, whereas the ED 30 for insulin binding to its receptor 
is 10 fold higher (1.33 nM). Recently, it was shown that a 
similar phenomenon is applicable for the relationship between 
insulin activation of insulin receptor kinase and insulin stimu- 
lation of glucose uptake in rat adipocytes. Glucose uptake was 
half-maximally or maximally stimulated, respectively, when 
only 4% or 14% of the maximal kinase activity had been 
reached. This could now be designated as "the spare receptor- 
kinase concept" (44). 
The signal transduction after the receptor is still an enigma 
(45). The link between the activated receptor, target enzymes 
and effector systems remains obscure. Progress in this area has 
been complicated by the pleiotropic nature of insulin action. 
Well described mechanisms of signal transduction, like cyclic 
nucleotides and ion channels, appear not to be central to insu- 
lin action (45,46). Another second messenger specific for insu- 
lin has not yet been found and it may not even exist. It appears 
that numerous intracellular factors interact with one-anotherto 
transduce the insulin signal depending on specific conditions 
in the cell (47). After interaction of insulin with its receptor and 
subsequent tyrosine kinase activation, one signal transduction 
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pathway involves a cascade of serine/threonine kinases also 
interacting with phosphatases which are regulated by phospho- 
rylation. This phosphorylation/dephosphorylation pathway is 
thought to control insulin-mediated glycogen metabolism (48). 
Another signal transduction pathway may involve the polar 
head group of an insulin-sensitive glycophospholipid which 
selectively inhibits lipolysis (49,50). The independent charac- 
ter of glucose and glycogen metabolism and lipolysis is reflected 
in the sensitivities of these effector systems for insulin. 
Antilipolysis is 3-5 fold more sensitive to insulin than glucose 
transport (51-53).  
It is now widely accepted that insulin stimulates glucose me- 
tabolism in its target tissues via recruitment of glucose trans- 
porters (GLUT) from a trans-Golgi pool to the plasma mem- 
brane (43). The action of insulin involves a transporter trans- 
location (54) and transporter activation (55). Recently, a num- 
ber of GLUT subtypes with diverse tissue distributions and 
relative abundances have been identified by molecular clon- 
ing and expression (56): (/) GLUT1 derived from human 
HepG2 cells and from rat and rabbit brain, also called the 
erythrocyte-type GLUT, is predominantly present in insulin- 
insensitive tissues, 00 GLUT2 is present in human and rat 
liver, and pancreatic islet cells, (Hi) GLUT3 derived from hu- 
man fetal muscle is expressed in all tissues, (iv) GLUT4 de- 
rived from human and rodent skeletal muscle and adipocytes, 
also called the insulin-regulatable GLUT, is present in insu- 
lin-sensitive tissues, (v) GLUTS derived from small intestine, 
and (v/) GLUT6 derived from small intestine, also called the 
NaVglucose cotransporter. 
•        Insulin resistance, sensitivity and responsiveness 
Insulin resistance, sensitivity and responsiveness were de- 
scribed and defined more than a decade ago (2,57,58). These 
terms used to indicate changes in the action of insulin still re- 
main a source of misunderstanding. To recapitulate, see Fig. 3 
(57): (/) insulin resistance exists whenever a certain concentra- 
tion of insulin produces a less than normal biologic response, 
00 insulin sensitivity is defined as the concentration of insu- 
lin necessary for a half-maximal effect (ED50), i.e. the relative 
position (left-right shift) of the dose-response curve, and (Hi) in- 
sulin responsiveness is defined as the maximal response (Vmax) 
to insulin. 
To fully characterize insulin action, a dose response curve has 
to be constructed. From Fig. 3 it is clear that alterations in 
insulin sensitivity and responsiveness can only then be evalu- 
ated. In general, it can be said that insulin sensitivity provides 
information to what extent the insulin triggered transmem- 
brane (receptor) and/or intracellular (receptor-coupled second 
messengers) signal transduction is functioning. Insulin respon- 
siveness provides information about the maximal capacity of 
the effector system to execute a certain biological effect. 
When the dose-response relationship between insulin and a 
certain biological effect is studied, an increase in insulin lev- 
els result in an increase both in receptor ligation and biologi- 
cal effect, until the crucial number of receptors (± 10% of the 
total receptor pool under normal conditions in the rat) (42) 
required to reach a maximal biological effect is occupied. 
Higher insulin levels lead to a further increase in insulin re- 
ceptor binding but this is without any further effect on the 
biological response. Some postreceptor step(s) are now rate- 
limiting for the measured biological effect. 
When insulin sensitivity and responsiveness are investigated 
in combination with an insulin receptor study, a detailed knowl- 
edge is obtained concerning the mechanism of insulin action. 
In general, it is accepted that a change in insulin sensitivity is 
partly influenced by a change in receptor number, affinity and 
function, whereas a change in insulin responsiveness is more 
likely to be influenced by postreceptor processes. Taken the 
spare receptor(-kinase) concept in mind, it is clear that a re- 
duction in the number and functionality of insulin receptors 
has to exceed the 90% level before receptor-mediated signal 
transduction becomes rate-limiting for insulin responsiveness. 
This 90% reduction is limited to a few rare genetic disorders, 
 
Figure 3. Dose-response curves for insulin action on a 
certain biological effect. Types of resistance to the ac- 
tion of insulin are shown. Adapted from Kahn (57). 
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•       Factors and conditions influencing insulin action 
From in vivo studies the ultimate physiological action of insu- 
lin can be determined in the intact organism, which in fact 
consists of a heterogenous mass of tissues. The biological ef- 
fect which is measured in vivo is the resultant of interactions 
between insulin and numerous interfering factors. The disad- 
vantage of in vivo studies is that interpretation of the data may 
be difficult since the metabolic environment is not exactly 
known and is subject to variations because all kinds of nega- 
tive and positive feedback mechanisms play an important role 
in the physiology of the body. 
When insulin action is studied in vivo, for example, by means 
of the hyperinsulinemic glucose clamp technique, insulin is 
infused in the body until a steady state plasma insulin level is 
obtained at which insulin action is quantitated. The problem 
with these studies is that when certain metabolic conditions 
are examined which are characterized by differences in the 
plasma clearance rate of insulin (59), insulin action will be 
quantitated at different plasma insulin concentrations. This 
makes a reliable comparison in insulin action between groups 
with differences in insulin clearance rate difficult. When one 
encounters this kind of problem, the only way to reach an ac- 
ceptable experimental set-up is to study a broad range of insu- 
lin levels and to construct dose-response curves. Now, the sen- 
sitivity for and the maximal effect of insulin can be deter- 
mined which makes a good comparison between groups pos- 
sible (60). 
In vivo, insulin has to be transferred across capillary endothe- 
lium when it is travelling from the blood to interstitial fluid and 
target tissues. This transfer seems to be conducted by a recep- 
tor-mediated process (61). In support of this observation is the 
fact that receptor-mediated transport of insulin across capillar- 
ies can be downregulatedby exposure to physiological levels of 
insulin (62). The transfer of insulin from blood to target tissue 
is described to be restricted (61) and can be rate-limiting for 
insulin action under certain conditions (63). For instance, half- 
maximal response to insulin occurs in perfused fat tissue at 100 
(lU/ml, whereas it occurs at 30 uU/ml in incubated tissue and 
at 8 uU/ml in incubated adipocytes (61). In addition, the time 
required for maximal response to insulin is longer in perfused 
tissue than in incubated cells and tissues. This is consistent with 
the finding that insulin is transported across vascular endothe- 
lial cells with a delay of 5-10 min (62) and that it takes approxi- 
mately 20 minutes before lymph insulin levels reach a steady 
state situation when plasma insulin levels are already in steady 
state (63). 
When studying insulin action on hepatic glucose production, 
at least two independent mechanisms seem to play a role. It is 
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is due to inhibition of glycogenolysis and/or gluconeogenesis. 
However, insulin may also attenuate hepatic glucose produc- 
tion through indirect action on peripheral tissues by restrict- 
ing the flux of gluconeogenic substrates like lactate, alanine, 
glycerol (64,65) and by restricting the flux of stimulators of 
gluconeogenesis (66,67) to the liver. When the latter mecha- 
nism plays an important role and insulin action is studied in 
vivo, different results will be obtained regarding hepatic glu- 
cose production when compared to liver perfusion studies. In 
this particular situation, comparison of in vivo and in vitro 
data may lead to conflicting conclusions when the mechanism 
of the studied biological process is not completely understood. 
The phenomenon just described might play an important role 
in the hepatic action of the recently discovered pancreatic p- 
cell hormone amylin, also called islet amyloid polypeptide (68- 
70). 
In vitro experiments enable us to study a certain tissue or cell 
type in detail without interference of other tissues or cells. 
Apart from that, each individual tissue or cell type can re- 
spond in its own specific way to certain stimuli or metabolic 
alterations. Although the metabolic and hormonal environ- 
ment in vivo is roughly similar to all tissues (with the exeption 
of the liver, which is exposed to higher hormonal and metabo- 
lite levels), each individual tissue can undergo specific alter- 
ations under several metabolic conditions (39,71). In general, 
insulin binding, receptor autophosphorylation and tyrosine ki- 
nase activity can differ from one tissue to another. During a 
change in the metabolic state of the organism, like long-term 
hyperinsulinaemia, diabetes, starvation and fat feeding, it has 
been reported that muscle, fat and liver each can undergo their 
own specific alterations in insulin signal transduction (60,72- 
77). 
It is often stated that the use of a well defined medium leads to 
an experimental set-up which allows the investigator to study 
one seperate factor and/or condition at the time of insulin ac- 
tion on a certain tissue or cell type. However, it is a misunder- 
standing that in vitro experiments can be considered free from 
disturbing factors and that the environment is constant during 
the experiment. Focused on insulin action, it is well known 
that an accumulation of free fatty acids in the incubation me- 
dium released by adipocytes after lipolysis influences insulin 
stimulated glucose uptake in a negative way (78). Without 
adding albumin to the incubation medium which binds free 
fatty acids, a time dependent suppression of insulin-stimulated 
glucose uptake will occur. Also, cells rapidly release adenos- 
ine, a potent antilipolytic agent, in the medium (52,79). In 
addition, a similar phenomenon has been described for pros- 
taglandins which are also released by cells (80). 
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•        Events leading to insulin resistance 
In general, modulation of insulin action can occur from the 
moment of insulin synthesis until the ultimate biological ef- 
fect is executed by a particular insulin-mediated effector sys- 
tem. The modulation of insulin action can be subdivided as 
follows: (/') P-cell insulin synthesis: (a) an abnormal insulin 
molecule, and (b) an incomplete conversion of proinsulin to 
insulin (2), (//') p-cell secretion: (a) a change in the amount 
(60,81-84) and pattern (20,85,86) of insulin release, and (b) a 
change in the release of amylin (68-70), (Hi) circulating insu- 
lin agonists and antagonists: (a) a change in the levels of hor- 
mones, neuropeptides, and cytokines, e.g. glucagon (87,88), 
catecholamines (89,90), corticosteroids (91), growth hormone 
(92), insulin-like growth factors (93), gestational hormones 
(94), calcitonin gene-related peptide (95), adenosine (96), pros- 
taglandins (80), and interleukines (97), and (b) antibodies to 
insulin receptors (2), (iv) circulating metabolites: a change in 
the levels of glucose (98-100), ketone bodies (101), and free 
fatty acids (78,88, 102), and (v) target tissue alterations: (a) a 
change in hepatic insulin extraction (13-19), (b) a change in 
insulin receptor function (103), (c) a change in postreceptor 
signal transduction (104,105), and (d) a change in insulin- 
mediated effector system, i.e. the end of the signal transduc- 
tion pathway, like changes in tissue glucose metabolites (106), 
enzyme activity (107), and GLUT (55). 
Several metabolic conditions have been reported to induce 
changes in insulin action and most of them induce insulin re- 
sistance. Obesity, non-insulin dependent diabetes mellitus, 
insulin dependent diabetes mellitus, disorders associated with 
increased production of counterregulatory (stress) hormones, 
hypertension, atherosclerotic cardiovascular disease, uremia, 
aging, and even bedrest are characterized by insulin resistance 
(108-115). Onlyphysical exercise is reported to improve insulin 
action (116-117). The data for body weight reduction, fasting 
and starvation are controversial (60,72,118-123). Each tissue 
is able to react in its own specific way when the entire body is 
subject to a change in the metabolic state. Therefore, one tissue 
might not reflect the whole body situation, and when two tis- 
sues are compared they might show contradictory results 
(39,72-76,124).        
MEASUREMENT OF IN VIVO INSULIN ACTION BY 
MEANS OF THE GLUCOSE CLAMP TECHNIQUE IN 
RATS 
• Evaluation of insulin action in v/'/ro, using isolated tis- 
sues or cells, may reflect in vivo action of the hormone, although 
there can be a dissociation between insulin action and/or receptor 
binding in vitro and the action of insulin in the intact organism. 
Therefore, to measure insulin-mediated metabolism in vivo, it is 
important to develop a technique which is able to accurately quan- 
titate insulin action in the intact organism (125,126). 
In 1936, Himsworth was the first investigator who introduced 
a standartized method to measure insulin action in vivo in the 
intact organism (127). By using the oral glucose tolerance test 
in conjunction with intravenous injections of insulin he was 
able to measure in vivo insulin action and showed that some 
diabetic patients were resistant to the action of insulin (128). 
For correct quantitation of insulin action however, one needs 
to know the relationship between stable plasma insulin levels 
and a certain specific insulin-mediated metabolic process. After 
the development of the radioimmunoassay for insulin (129), 
investigators were able to measure plasma insulin concentra- 
tions. Since then many techniques have been introduced to 
assess insulin action in vivo. These techniques have critically 
been reviewed (126). One of these methods, the glucose clamp 
technique, is now the most widely accepted approach to quan- 
titate insulin action in vivo and is considered the "golden stan- 
dard". 
We will briefly describe the method to measure insulin action 
in vivo by means of the glucose clamp technique in undis- 
turbed, freely moving rats (60,130).  
• Principle of the hyperinsulinaemic, euglycaemic 
clamp technique  
The plasma insulin concentration is acutely raised and main- 
tained at a constant level by means of a primed-continuous 
systemic infusion of insulin at a constant rate. When insulin 
starts to act, by inhibiting hepatic glucose production and 
stimulating peripheral tissue glucose uptake, plasma glucose 
levels decrease. This is detected by frequent measurement (ev- 
ery 5-10 min) of plasma glucose levels and counteracted by a 
simultaneous variable infusion of glucose to maintain 
euglycemia. After 30-60 min, when full action of insulin is 
achieved, a steady-state situation is reached during which 
plasma insulin and glucose levels and glucose infusion rate 
are constant. In this situation, the exogenous glucose infusion 
rate is a rough reflection of whole body glucose uptake at that 
particular plasma insulin level. An example of the clamp in 
normal and diabetic rats is presented in Fig.4. This example 
shows the dynamics in glucose infusion rate and plasma glu- 
cose levels during a 4-step sequential hyperinsulinaemic 
euglycaemic clamp. The sequential, dose-response clamp al- 
lows discrimination between insulin sensitivity and insulin 
responsiveness in one single experiment. Because the body 
also contains a potential endogenous source of glucose ap- 
pearance, namely the liver, an exact quantitation of whole body 
glucose uptake is not possible during the clamp. Precise mea- 
surement of glucose uptake can only be achieved when the 
clamp technique is conducted in conjunction with a continu- 
ous infusion of radiolabeled glucose (60,130). Thus, by mea- 
suring plasma glucose specific activity, exact calculation of 
glucose turnover is possible. Glucose turnover is a direct re- 
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Figure 4. Insulin infusion rates, plasma glucose concentrations, and glucose infusion rates in normal and streptozotocin- 
induced diabetic rats during insulin/glucose clamp. A 4-step sequential (dose response) hyperinsulinaemic, euglycaemic 
clamp is shown with insulin infusion steps of 90 min each. The final 25 min of each individual insulin infusion step, 
when steady state is present, is used for quantitation of insulin action. 
  
flection of whole body glucose uptake. Under steady-state 
conditions, glucose uptake equals the sum of exogenous glu- 
cose infusion and hepatic glucose production. Since glucose 
uptake and infusion can be measured, hepatic glucose produc- 
tion can be calculated from the equation. To assure that no 
glucose enters or leaves the plasma glucose compartment un- 
detected and thus obscures the rate of appearance (Ra) and 
the rate of disappearance (Rd) of glucose, rats have to be fasted 
for at least 4 hours before a clamp can be performed and uri- 
nary glucose loss has to be measured. After 4 hours of fast- 
ing, there is no substantial glucose delivery from the intestine 
to the plasma glucose compartment. In addition, during 
euglycaemic clamps, no glucose passes the kidneys since the 
threshold for glucose is at 10 mmol/1. When hyperglycaemic 
clamps are performed, urinary glucose loss has to be mea- 
sured and taken into account. The above discussed ins and outs 
of the glucose clamp technique are depicted in Fig.5. 
• To clamp rats in a proper way, a few criteria have 
to be met 
•        Sampling site          
The assumption of the clamp technique is that the rate of glu- 
cose infusion plus endogenous (hepatic) glucose production 
equals the rate of whole body glucose uptake. Insulin-stimu- 
lated whole body glucose uptake can be directly compared 
between groups of rats each characterized by different meta- 
bolic conditions, when the level of glycaemia to which glu- 
cose-utilizing tissues are exposed is the same. Glucose is able 
to promote its own uptake by mass action (130). Within the 
physiological range an elevation of plasma glucose levels re- 
sults in an increase of whole body glucose uptake. Therefore, 
to accurately study the effect of insulin on glucose metabo- 
lism, one has to match the arterial glucose concentrations. 
For this reason arterial sampling is recommended. The result   
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Figure 5. Schematic representation of the glucose fluxes during the hyperinsulinaemic, euglycaemic clamp technique. 
Peripheral tissue glucose uptake is the same and referred to in the text as whole body glucose uptake. Ra - rate of appear- 
ance, Rd-rate of disappearance. 
  
clamping is that a systematic error occurs if rats are compared 
at equivalent venous glycaemia and insulinaemia when their 
sensitivities to insulin are not identical. The more sensitive to 
insulin, the greater the arteriovenous glucose difference across 
the peripheral tissues. If venous glycaemia is identical, arte- 
rial glycaemia is highest in the rat most sensitive to insulin. 
In this situation, whole body glucose uptake is not compared 
at matched glycaemia and glucose uptake will be overestimated 
in the rat with a high insulin sensitivity since the clamp is 
performed at higher arterial glycaemia. 
•        Anesthesia 
It has repeatedly been shown that anesthesia exhibits a great 
impact on glucose metabolism. Pentobarbital anesthesia in- 
duces an inhibition of the central nervous system which is 
reflected in a disbalance of plasma catecholamine levels, body 
temperature, heart rate and blood pressure (131,132). This 
results in a changed glucose kinetics. Glucose turnover, using 
3
H-glucose as a tracer, show that a transient increase in he- 
patic glucose production occurs and peripheral tissue glucose 
uptake decreases by 30% as compared with conscious rats 
(133). Pentobarbital anesthesia increases hepatic synthesis of 
glycogen from the gluconeogenic precursors alanine and pyru- 
vate in rats (134). From these data it is clear that the hyperinsu- 
linaemic, euglycaemic clamp technique should be performed 
in conscious rats. Since carbohydrate metabolism is under di- 
rect control of the central nervous system, an undisturbed awake 
rat model would provide a more reliable physiological reflec- 
tion of hepatic glucose production and peripheral tissue glu- 
cose uptake as measured during the clamp. The experimental 
set-up for clamping conscious rats is depicted in Fig.6, by us- 
ing a modification of techniques previously described 
(135,136). 
•        Compensation of blood loss    
During a 7.5 hour lasting 5-step sequential clamp, ±2 ml of 
blood is sampled during each individual insulin infusion step. 
Since a rat of 350 g contains approximately 20 ml of blood, it 
is obvious that long-term clamping must be accompanied by 
blood transfusion which compensates for blood loss. To achieve 
this, fresh prewarmed (38°C) donor blood obtained by heart 
puncture from littermates is returned to the experimental ani- 
mal via the arterial blood sampling cannula. To prevent clot- 
ting, donor blood is supplemented with 25 lU/ml heparin or 3 
mg/ml citrate. During the first 15 min of each individual in- 
sulin infusion step, 3 samples of 0.7 ml donor blood are trans- 
fused into the rat to avoid disturbances and dilution of plasma 
3
H-glucose specific activity during the steady state period (70- 
90 min) of the clamp, when insulin action is quantitated. An 
alternative way of transfusing donor blood to the experimen- 
tal animal is by continuous infusion through the venous 
cannula. When insulin is infused during the clamp procedure, 
insulin can be mixed with saline-diluted donor blood instead 
of pure saline. High frequency blood sampling and transfu- 
sion of donor blood in awake rats have been shown not to 
influence the secretion of stress hormones like prolactin and 
corticosterone. Blood composition remaines normal and no 
metabolic alterations could be detected (137-139).   
38 Koopmans and Radder 
 




Figure 6. Experimental set-up for clamping conscious rats. The rat is placed in a metabolic cage allowing the collection of 
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